Back to top

Curis announces eleven active clinical sites in TakeAim CLL study

Curis (CRIS) announced that eleven clinical sites have been initiated and are now open for patient enrollment in its Phase 2 TakeAim CLL study eval...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Curis, Inc. (CRIS)